Inactivation of HIV infectivity by the chlorite-oxygen reaction product tetrachlorodecaoxygen.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Inactivation of HIV infectivity by the chlorite-oxygen reaction product tetrachlorodecaoxygen.

AIDS. 1993 Sep;7(9):1205-12. Unique Identifier : AIDSLINE MED/94030751
Ennen J; Werner K; Kuhne FW; Kurth R; Paul-Ehrlich Institute, Langen, Germany.

Abstract: OBJECTIVE: Since the chlorite-oxygen reaction product tetrachlorodecaoxygen (TCDO) anion complex promotes efficaciously tissue repair and has antibacterial activity, our aim was to determine the effects of TCDO on the replication of HIV and on the infectivity of free HIV particles. DESIGN: The effects of TCDO on cellular HIV replication machinery and the consequences of TCDO for infectivity of HIV virions were evaluated. METHODS: Virus yields in supernatants of TCDO-supplemented cultures of HIV-infected cells or virus infectivity in TCDO-treated virus stocks were quantified by titration assays and then calculating the 50% tissue culture infectious dose. RESULTS: First, TCDO did not affect the replication of HIV in persistently infected lymphocytic and monocytic cell lines or in peripheral blood mononuclear cells. Second, supplementation of HIV stocks with TCDO markedly decreased the infectivity of HIV particles in a concentration dependent manner. Third, the binding of gp120 envelope glycoprotein of HIV-1 to cells is blocked by pre-incubation with TCDO. Fourth, the inhibition of HIV replication by the reverse transcriptase inhibitor 3'-azido-3'-deoxythymidine (zidovudine) in de novo infected cell cultures was not affected by the simultaneous addition of TCDO. However, the delayed virus spread of HIV in cultures in the presence of suboptimal concentrations of zidovudine could significantly be blocked by the simultaneous addition of TCDO. Fifth, TCDO failed to induce the chromosomally integrated HIV-1 provirus in the T-lymphoma cell line ACH2. CONCLUSIONS: TCDO appears to inactivate HIV particles directly, but has no influence on the intracellular replicative machinery of HIV. Our results suggest that a clinical evaluation of the TCDO complex as chemotherapy for HIV infection and full-blown AIDS should be considered, particularly in patients concomitantly receiving zidovudine.

Keywords: Antiviral Agents/*PHARMACOLOGY Cells, Cultured Chlorine/*PHARMACOLOGY Didanosine/PHARMACOLOGY Drug Interactions Human HIV Envelope Protein gp120/METABOLISM HIV-1/*DRUG EFFECTS/GENETICS/PATHOGENICITY HIV-2/*DRUG EFFECTS/GENETICS/PHYSIOLOGY/PATHOGENICITY Oxides/*PHARMACOLOGY Tumor Cells, Cultured Virus Activation/DRUG EFFECTS Virus Replication/DRUG EFFECTS Zidovudine/PHARMACOLOGY JOURNAL ARTICLE
940228
M9420770

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .